Kiyoshi Eshima

Title: Kiyoshi Eshima: Innovator in Cancer Treatment

Introduction

Kiyoshi Eshima is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of blood cancer. With a total of 9 patents to his name, Eshima's work focuses on developing effective therapies with minimal side effects.

Latest Patents

Eshima's latest patents include a groundbreaking therapy and new therapeutic agent for blood cancer. The objective of this invention is to provide a new means for treating or ameliorating blood cancer patients, emphasizing high efficacy and reduced side effects. This combined medicine comprises 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof, along with venetoclax or a salt thereof. Another significant patent involves a method for stabilizing humidity-sensitive pharmaceutical substances, specifically DFP-11207, which is unstable at high humidity. This invention provides a stabilized preparation, including a capsule formulation for cancer treatment that contains DFP-11207 or a pharmaceutically acceptable salt and a hygroscopic agent.

Career Highlights

Throughout his career, Kiyoshi Eshima has worked with prominent companies in the pharmaceutical industry. He has been associated with Delta-Fly Pharma, Inc. and Taiho Pharmaceutical Company Limited. His work in these organizations has contributed to advancements in cancer treatment and pharmaceutical development.

Collaborations

Eshima has collaborated with notable colleagues, including Tatsuhiro Ishida and Masakazu Fukushima. These partnerships have fostered innovation and progress in their shared field of expertise.

Conclusion

Kiyoshi Eshima's contributions to cancer treatment through his innovative patents highlight his dedication to improving patient outcomes. His work continues to influence the pharmaceutical landscape, making a significant impact on the treatment of blood cancer.